Karl Hudspith is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Karl advises start-up companies in the biotech, medical device, and pharmaceutical spaces who are bringing the next generation of diagnostics and therapeutics to the clinic.
Prior to joining the firm, Karl obtained his bachelor’s degree in biology at Oxford Brookes University, before completing a Ph.D. in clinical neurosciences at the University of Oxford. During Karl’s doctoral work, he helped develop a next-generation sequencing based DNA diagnostic test for patients with inherited retinal degenerations which was introduced into the NHS in Oxfordshire. Karl was part of the team that discovered that mutations in the PIGQ and CBL genes are a cause of Ohtahara syndrome, a rare and fatal form of early-onset epilepsy.
Karl completed his post-doctoral fellowship at the Wilmer Eye Institute at Johns Hopkins University. He worked in the lab of Dr. Mandeep Singh with the aim of developing a stem-cell-based regenerative medicine treatment for inherited retinal degenerations. He was the 2015 and 2018 recipient of the Juliette RP Vision Foundation Young Scientist Award.
Karl represented Great Britain at the World Rowing Cup in 2013, is a two-time world university rowing champion, and three-time winner of the Oxford-Cambridge boat race. Learn more about his sporting history on Wikipedia.
Karl Hudspith is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Karl advises start-up companies in the biotech, medical device, and pharmaceutical spaces who are bringing the next generation of diagnostics and therapeutics to the clinic.
Prior to joining the firm, Karl obtained his bachelor’s degree in biology at Oxford Brookes University, before completing a Ph.D. in clinical neurosciences at the University of Oxford. During Karl’s doctoral work, he helped develop a next-generation sequencing based DNA diagnostic test for patients with inherited retinal degenerations which was introduced into the NHS in Oxfordshire. Karl was part of the team that discovered that mutations in the PIGQ and CBL genes are a cause of Ohtahara syndrome, a rare and fatal form of early-onset epilepsy.
Karl completed his post-doctoral fellowship at the Wilmer Eye Institute at Johns Hopkins University. He worked in the lab of Dr. Mandeep Singh with the aim of developing a stem-cell-based regenerative medicine treatment for inherited retinal degenerations. He was the 2015 and 2018 recipient of the Juliette RP Vision Foundation Young Scientist Award.
Karl represented Great Britain at the World Rowing Cup in 2013, is a two-time world university rowing champion, and three-time winner of the Oxford-Cambridge boat race. Learn more about his sporting history on Wikipedia.
- J.D., Georgetown University Law Center, 2023
- Ph.D., Clinical Neurosciences, University of Oxford, 2016
- B.S., Biology, Oxford Brookes University, 2010
- Bar of the District of Columbia
- State Bar of Maryland
- U.S. Patent and Trademark Office
- J.D., Georgetown University Law Center, 2023
- Ph.D., Clinical Neurosciences, University of Oxford, 2016
- B.S., Biology, Oxford Brookes University, 2010
- Bar of the District of Columbia
- State Bar of Maryland
- U.S. Patent and Trademark Office
Select Matters
- Advised Karius on IP matters related to its $100 million Series C financing
Select Matters
- Advised Karius on IP matters related to its $100 million Series C financing
Select Publications
- Co-author, “Proof of Principle: Preclinical data on Retinal Cell Transplantation” in Cell-Based Therapy for Degenerative Retinal Disease 11-29, 2019
- Co-author, “Development of imaging biomarkers of photoreceptor transplantation outcomes in mice based on confocal scanning laser ophthalmoscopy,” 59(9) Investigative Ophthalmology & Visual Science 5839, 2018
- Co-author, “Development of an experimental cell preparation and delivery protocol to the murine subretinal space using 27-gauge vitreoretinal surgery instruments,” 58(8) Investigative Ophthalmology & Visual Science 5972, 2017
- Co-author, “De novo point mutations in patients diagnosed with ataxic cerebral palsy,” 138(7) Brain 1817-1832, 2015
- Co-author, “Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis,” 23(12) Hum Mol Genet 3200-3211, 2014
- Co-author, “Next-generation sequencing (NGS) as a diagnostic tool for retinal degeneration reveals a much higher detection rate in early-onset disease,” 21(3) Eur J Hum Genet 274-280, 2013
Select Publications
- Co-author, “Proof of Principle: Preclinical data on Retinal Cell Transplantation” in Cell-Based Therapy for Degenerative Retinal Disease 11-29, 2019
- Co-author, “Development of imaging biomarkers of photoreceptor transplantation outcomes in mice based on confocal scanning laser ophthalmoscopy,” 59(9) Investigative Ophthalmology & Visual Science 5839, 2018
- Co-author, “Development of an experimental cell preparation and delivery protocol to the murine subretinal space using 27-gauge vitreoretinal surgery instruments,” 58(8) Investigative Ophthalmology & Visual Science 5972, 2017
- Co-author, “De novo point mutations in patients diagnosed with ataxic cerebral palsy,” 138(7) Brain 1817-1832, 2015
- Co-author, “Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis,” 23(12) Hum Mol Genet 3200-3211, 2014
- Co-author, “Next-generation sequencing (NGS) as a diagnostic tool for retinal degeneration reveals a much higher detection rate in early-onset disease,” 21(3) Eur J Hum Genet 274-280, 2013
- Privacy Policy
- Terms of Use
- Accessibility